# Draft Scientific Program as at 17 September 2015

#### Saturday 28 November 2015

14:00 – 16:00 APSA – ASCEPT OSCE workshop				
	Venue: University of Tasmania, Medical Sciences Precinct, Medical Science 2 Building, Level 4, Room 444			

#### **Sunday 29 November 2015**

	10:00 – 13:00	10:00 – 12:00	12:30 - 16:30			
	ASCEPT board meeting	Pharmacogenomics workshop	APSA – ASCEPT Education			
14:30 - 16:30	APSA - ASCEPT	APSA - ASCEPT	Forum			
	Careers workshop	Clinical Pharmacology workshop	Benchmarking			
			Dr Sara Booth, The University			
			of Tasmania			
			Blended learning			
			Education forum AGM			
			Sponsored by			
			Therapeutic Guidelines			
17:00 – 17:10	Conference opening	Cardioannes				
	Assoc Prof Parisa Aslani, President, Al	Sponsored by				
	Assoc Prof Peter Molenaar, President	UNIVERSITY of TASMANIA				
17:10 - 18:00	Opening keynote address	TASMANIA				
	And then there were three – lessons from a convoluted drug development project					
	Prof Martin Michel, Professor of Pharmacology, Johannes Gutenberg University, Germany					
18:00 – 19:30	Welcome reception					
	Hotel Grand Chancellor Hobart, Mezzanine Level					

## **Monday 30 November 2015**

08:30 - 9:30	British Pharmacological Society keynote address					
	Pharmacogenetics including personalisation of treatment in cardiovascular disease through next generation sequencing in adverse drug reactions  Dr Ana Alfirevic, University of Liverpool, UK					
09:30 - 10:25	Morning tea and poster presentations					
10:30 - 12:30	Symposium 1: Misuse of pharmaceuticals and herbal medications: Epidemiology and implications Pharmaceutical drug misuse: Implications for post-market surveillance Prof Nicholas Buckley, The University of Sydney Opioid substitution therapy among prisoners: Longitudinal findings from a data linkage study Dr Natasa Gisev, University of New South Wales Misuse of herbal medicines: An emerging issue Dr lan Musgrave, The University of Adelaide Trends in acute pharmaceutical drugrelated harms Assoc Prof Belinda Lloyd, Monash University	Symposium 2: Discovery and development of novel anti-fibrotic therapies  Bench to bedside — development of novel treatment for diabetic nephropathy Prof Darren Kelly, University of Melbourne Role of oxidative stress in development of pulmonary fibrosis? Assoc Prof Ross Vlahos, RMIT University Relaxin: A pleiotropic hormone with potent anti-fibrotic actions Assoc Prof Chrishan Samuel, Monash University Novel targets to treat cardiac fibrosis Dr Tracey Gaspari, Monash University	Symposium 3: Pharmacokinetic challenges to drug development and clinical implementation  The Pharmacokinetic intersection of academia, hospital and pharmaceutical industry Dr Vidya Perera, University of Sydney Dose individualisation of sunitinib and tamoxifen Assoc Prof Howard Gurney, Westmead Hospital Across the continuum: DMPK experiences from preclinical to market Dr Bill Smith, Gilead Sciences	Symposium 4: Recent advances and therapeutic developments in purinergic signalling Sensory purinergic mechanism in the gastrointestinal system Prof Simon Brookes, Flinders University Effect of infection and inflammation on purinergic signalling in the urinary bladder: a trigger for Detrusor Overactivity? Prof Kylie Mansfield, University of Woollongong P2X1-purinoceptor antagonists as potential male contraceptives Dr Sab Ventura, Monash University Postjunctional GPCR regulation of lower urinary tract purinergic responses Prof Russ Chess-Williams, Bond University		
12:30 – 13:25	Lunch with exhibitors and poster presentations			APSA Council Meeting		
13:30 – 15:30	Oral presentations 1	Oral presentations 4				
15:30 - 15:55	Afternoon tea with exhibitors					
16:00 – 18:00	Oral presentations 5	Oral presentations 6	Oral presentations 7	Oral presentations 8		

## **Tuesday 1 December 2015**

07:45 - 08:20	APSA AGM					
08:30 – 9:30 APSA Medal Oration						
09:30 - 10:25	Morning tea and poster pre	and poster presentations  Sponsored by			THE UNIVERSITY OF PHARMACOLOGY MELBOURNE & THERAPEUTICS	
10:30 - 12:30			Prof Brian Ya University of Embedding oriented lea science prac Dr Kirsten Zi University of	mes do we regraduates? ates, The forming into ctical classes mbardi, The followers are ready  Orlando, versity erspective ready" hnston,	Ethnicity and personalised medicine  Ethnopharmacology: From drugs to medicines for all populations Dr Annette Gross, GlaxoSmithKline CYP2C19 genetics in Maori and Pacific peoples Dr Nuala Helsby, University of Auckland Personalised medicines for Aboriginal Australians Prof Andrew Somogyi, University of Adelaide Interethnic differences in pain, analgesia and neuroimmunogenetics Dr Daniel Barratt, University of Adelaide	
12:30 – 13:25	Lunch with exhibitors and poster presentations					
13:30 – 15:30	Oral presentations 9 ASCEPT Garth McQueen Oral Prize	Oral presentations 10	Oral present	tations 11	Oral presentations 12	
15:30 – 15:55	5 Afternoon tea with exhibitors					
16:00 – 17:00	ASCEPT Rand Medal lecture					
17:00 – 18:00	ASCEPT AGM					
19:00 – 22:30	Meeting dinner Hobart Function and Conference Centre, 1 Elizabeth Street Pier, Hobart					

## Wednesday 2 December 2015

08:30 - 9:30	Jananese Pharmacological Society keynote address					
08:30 - 9:30	Japanese Pharmacological Society keynote address  Transporters in pharmacology and molecular target drug discovery					
	Prof Yoshikatsu Kanai, Osaka University, Graduate School of Medicine, Japan					
9:30 - 10:25	Morning tea and poster presentations					
10:30 – 12:30	Symposium 9: Adverse drug reactions, is electronic prescribing a panacea?	Symposium 10: An up-close look at novel targets for breast cancer	Symposium 11: Novel approaches to drug safety: Beyond randomised controlled trials	Symposium 12: Denis Wade Johnson & Johnson New Investigators		
	The burden of ADRs Assoc Prof Simon Bell, Monash University The misdiagnosis of ADRs Assoc Prof Matt Doogue, Otago University ADRs: moving from paper to electronic systems Prof Johanna Westbrook, Australian Institute of Health Innovation, Macquarie University eSystems decision support, a panacea for ADRs? Dr Sepehr Shakib, Royal Adelaide Hospital	Morphine modulates breast cancer metastatic potential Assoc Prof Marie-Odile Parat, The University of Queensland Inflammation resolution mediators in breast cancer Prof Alastair Stewart, University of Melbourne UDP-glucuronosyltransferases (UGTs) and steroid hormone regulation in breast cancer Dr Robyn Meech, Flinders University Development of a novel class of omega-3-fatty acid epoxide analogues with in vivo activity against breast cancer Prof Michael Murray, University of Sydney	Ms Tara Quirke, Consumer Dementia Research Network, Alzheimer's Australia Genetic screening for people at risk of adverse drug events: Costs vs. benefits from the individual and societal perspective Prof Danny Liew, The University of Melbourne Non-experimental evaluation of medical products: challenges and established approaches Assoc Prof Alan Brookhart, University of North Carolina Register-based pharmacoepidemiology — Insights from research using the Nordic prescription databases Dr Jenni Ilomäki, Monash University	The small-molecule formyl peptide receptor agonist compound 17b limits myocardial reperfusion injury in vivo: Unmasking ligand biased agonism as a novel cardioprotective mechanism  Dr Chengxue Qin, Baker IDI Heart & Diabetes Institute  Adrenoceptors promote glucose uptake into adipocytes and muscle by an insulinindependent signalling pathway involving mTORC2  Dr Masaaki Sato, Monash University  Denise Wooten, Monash University  Felicity Davis, The University of Queensland; University of Cambridge		
12:30 – 13:25						
13:30 – 15:00	Oral presentations 13	Oral presentations 14	Oral presentations 15	Oral presentations 16		
15:00 – 15:15	Short comfort break					
15:15 - 16:15	APSA lecture					
16:15-16:45	Awards and close					